Non-Small Cell Lung Cancer: Update Bulletin [Jan 2016]
Gain new KOL insights on the latest events that have the potential to shape the targeted treatment of Non-Small Cell Lung Cancer (NSCLC). Topics covered include opinions about Tagrisso (osimertinib; AstraZeneca) as a newly approved second-line treatment for EGFR T790M mutation-positive NSCLC, the approval of Portrazza (necitumumab; Eli Lilly) for first-line squamous NSCLC therapy, and the expansion of the label for Xalkori (crizotinib; Pfizer) to include the first-line treatment of patients in the EU with ALK-positive NSCLC and patients in the US with ROS1-positive advanced NSCLC. KOLs also discuss Alecensa (alectinib; Roche) following its approval as a second-line treatment for ALK-positive metastatic NSCLC, and assess topline KEYNOTE-010 trial data for Keytruda (pembrolizumab; Merck & Co.) in the second-line treatment of PD-L1 positive advanced NSCLC.
Key Questions Answered in this Update Bulletin:
Key Questions Answered in this Update Bulletin:
- Will the safety and efficacy of AstraZeneca’s Tagrisso prove sufficient to position it as the second-line treatment of choice for EGFR T790M mutation-positive NSCLC?
- Is the overall survival (OS) advantage shown by Eli Lilly’s Portrazza over chemotherapy likely to justify its cost as a first-line therapy for squamous NSCLC?
- If approved, how widespread is the use of Pfizer’s Xalkori as a first-line treatment for ALK-positive advanced NSCLC, in the EU, likely to be?
- As Xalkori awaits approval for the treatment of ROS1-positive metastatic NSCLC in the US, how successful do KOLs think the agent will be in this setting?
- Can the favourable toxicity profile and significant CNS activity of Roche’s Alecensa help it to secure a role as standard treatment for second-line ALK-positive metastatic NSCLC?
- To what extent will the OS advantage shown by topline KEYNOTE-010 data impact the use of Merck’s Keytruda as a second-line treatment for PD-L1 positive advanced NSCLC?
